Schering Clarinex Reditabs approved
Executive Summary
Schering-Plough's Clarinex Reditabs 5 mg clears FDA June 26 for treatment of allergy symptoms and chronic idiopathic urticaria. Product launch is "pending FDA approval of a quality control test revision, the supplement for which has already been submitted, and the build-up of sufficient inventories," the company said. Reditabs have been "approvable" since December (1"The Pink Sheet" Dec. 24, 2001, p. 34)...